Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.77 |
| ▸ | RAF1 | P04049 | 14/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | BRAF | P15056 | 7/20 | 0.66 |
| ▸ | KDR | P35968 | 5/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.66 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.66 |
| ▸ | FLT1 | P17948 | 2/20 | 0.66 |
| ▸ | MAOA | P21397 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939451 | 0.92 | RAF1 (0.83) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL939971 | 0.90 | RAF1 (0.70) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL14453625 | 0.90 | GSK3B (0.71) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL14453621 | 0.90 | GSK3B (0.71) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL14453608 | 0.89 | RET (0.70) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL937921 | 0.89 | RAF1 (0.71) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL14453626 | 0.88 | GSK3B (0.69) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL14453628 | 0.88 | RET (0.66) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL1506380 | 0.87 | RET (1.00) | RETRAF1GSK3BBRAFKDR | |
| SCHEMBL14453619 | 0.86 | GSK3B (0.66) | RETRAF1GSK3BBRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113614-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | CARSGEN THERAPEUTICS CO., LTD. (CN) | 2021-04-22 | — | — | US | claimed |
| EP-3747433-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | Carsgen Therapeutics Co., Ltd. (CN) | 2020-12-09 | — | — | EP | claimed |
| WO-2019149279-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | 科济生物医药（上海）有限公司 | 2019-08-08 | — | — | WO | claimed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | claimed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | claimed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | claimed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | claimed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | claimed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | claimed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | claimed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | claimed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | RET 182/4885RAF1 2/4885GSK3B 1176/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RET 128/4885RAF1 2/4885GSK3B 995/4885 |
| US-20210113614-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | CD47, IL2RA, IL2 | RET 76/4885RAF1 470/4885GSK3B 3271/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | RET 170/4885RAF1 3/4885GSK3B 1155/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RET 182/4885RAF1 2/4885GSK3B 1176/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RET 182/4885RAF1 2/4885GSK3B 1176/4885 |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | MAPK1, MAPK8, MAPK3 | RET 1583/4885RAF1 452/4885GSK3B 1106/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | RET 70/4885RAF1 4/4885GSK3B 996/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RET 182/4885RAF1 2/4885GSK3B 1176/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | RET 231/4885RAF1 3/4885GSK3B 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.